Delcath Systems (DCTH) Projected to Post Quarterly Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) is anticipated to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.0971) per share and revenue of $23.5060 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. The company had revenue of $20.73 million for the quarter, compared to analyst estimates of $20.35 million. Delcath Systems had a net margin of 3.17% and a return on equity of 2.63%. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH traded up $0.51 during trading on Tuesday, hitting $11.53. 440,882 shares of the company were exchanged, compared to its average volume of 420,136. The stock has a market capitalization of $397.27 million, a P/E ratio of 164.71 and a beta of 0.54. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $18.23. The firm’s 50 day moving average price is $9.77 and its 200-day moving average price is $9.83.

Hedge Funds Weigh In On Delcath Systems

Institutional investors have recently modified their holdings of the business. California State Teachers Retirement System purchased a new stake in Delcath Systems in the 2nd quarter valued at $26,000. Russell Investments Group Ltd. purchased a new position in Delcath Systems during the 3rd quarter worth $29,000. Tower Research Capital LLC TRC acquired a new position in Delcath Systems in the second quarter valued at $40,000. Legal & General Group Plc purchased a new stake in shares of Delcath Systems in the second quarter valued at about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Delcath Systems in the second quarter valued at about $151,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on DCTH. BTIG Research cut their price target on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wall Street Zen downgraded shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Evercore set a $27.00 price objective on Delcath Systems in a report on Thursday, February 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Delcath Systems in a report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Delcath Systems has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.